Fresh Tracks Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Albert Nicholas Marchio II
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5777 Central Avenue Boulder CO United States of America 80301
- IPO Date
- Mar 10, 1993
- CIK
- 0000819050
- Website
- frtx.com
- Similar Companies
- Business
- Fresh Tracks Therapeutics, Inc. (FRTX) operates as a clinical-stage pharmaceutical company focused on the development of innovative prescription therapeutics targeting autoimmune, inflammatory, and other debilitating diseases; its pipeline previously featured new chemical entities including FRTX-02, a potent, highly selective oral DYRK1A inhibitor that completed Phase 1 clinical trials demonstrating safety and tolerability for potential once-daily treatment in autoimmune and inflammatory conditions, FRTX-10, a preclinical covalent stimulator of interferon genes (STING) inhibitor candidate for autoimmune, inflammatory, and rare genetic diseases, and a platform of next-generation kinase inhibitors targeting DYRK, LRRK2, TTK, and CLK. The company, founded in 2009 and headquartered in Boulder, Colorado, previously conducted operations primarily in the United States with a focus on modulating adaptive and innate immune responses to address unmet needs in immune-mediated diseases. In a major strategic shift, Fresh Tracks Therapeutics discontinued all clinical and preclinical development programs in October 2023, terminated most employees, and initiated a plan of liquidation and dissolution approved by its Board following an unsuccessful review of strategic alternatives including mergers and acquisitions; the company plans to file a Certificate of Dissolution effective February 28, 2025, with an initial cash distribution of approximately $6.3 million to eligible stockholders and warrant holders on that date, after which its common stock will cease trading on the OTC Pink Market.
Fresh Tracks Therapeutics Announces Hearing Date and Notice of Proposed Consent Judgement Regarding Dissolution of Company
Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th
Fresh Tracks Therapeutics Announces Listing on OTC Pink Market
Fresh Tracks Therapeutics Announces its Common Stock will be Suspended from Trading on Nasdaq at Open of Business on December 19th
Fresh Tracks Therapeutics Announces Third Adjournment of Special Meeting of Stockholders
Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders
Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders
Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix
Why Is Fresh Tracks Therapeutics (FRTX) Stock Up 92% Today?
Best Penny Stocks To Buy? 4 To Watch In January 2023
Fresh Tracks Therapeutics, Inc. (FRTX) Q3 2022 Earnings Call Transcript
Fresh Tracks Therapeutics (FRTX) Reports Q3 Loss, Tops Revenue Estimates
Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022
Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2022 Results - Earnings Call Transcript